Mesenchymal stromal cells (MSCs) are emerging as a helpful therapeutic tool for the treatment of graft-versus-host disease (GvHD). 1, 2 Nevertheless, efficacy studies have been scarcely corroborated by immune monitoring of patients' response after cell infusion. The analysis of clinical samples from GvHD patients treated by MSCs represents a unique possibility to understand the events leading in vivo to GvHD improvement. With the aim to provide the scientific basis for novel and better-tailored protocols for managing steroid-resistant GvHD, we investigated at a cellular and molecular level the disease course, before and after MSC infusion. Ten patients with post-transplant GvHD were enrolled in the study. Details of patients' characteristics are reported in Table 1 . Six patients were enrolled for acute GvHD (aGvHD) and four for overlap syndrome or active chronic GvHD (cGvHD) resistant to first line steroid-based therapy.
All patients were treated with multiple infusions of third-party bone marrow-derived MSCs. Patients received from 2 to 5 cell infusions. The median dose of cells infused was 1 Â 10 6 /kg (range ¼ 0.9 --2.9 Â 10 6 /kg). Consistent with our previous study, 3 we confirmed a response rate of around 70% overall, with a complete response in 30% of the patients. Moreover, it is very important to underline that even patients presenting a partial response to MSCs could taper ongoing treatment without the need of additional lines of treatment, thus lowering the burden of immunosuppression in a very critical phase after transplantation with high risk of infections.
To corroborate clinical observations about the response of enrolled patients to MSC therapy, we monitored GvHD course at a molecular level, taking advantage of two biomarkers for aGvHD interleukin 2 receptor alpha (IL-2Ra) and tumor necrosis factor receptor (TNFR) I. These markers, recently identified and validated by the Ferrara's group, 4 present high differential expression between transplanted patients developing or not GvHD. ELISA monitoring of TNFRI ( Figure 1a) showed that mean plasma levels of aGvHD patients before MSC infusions were 3.89 ng/ml (range ¼ 0.91 --10.58, n ¼ 6), significantly higher than healthy donors (HD) (mean level ¼ 0.74 ng/ml, range ¼ 0.58 --0.95, n ¼ 12, Po0.01). Interestingly, also TNFRI plasma concentrations of patients with active cGvHD resulted, before MSC infusions, higher than HD (mean level ¼ 4.2 ng/ml, range ¼ 1.21 --8.53, n ¼ 4, Po0.01). After MSC infusions, patients with steroid-resistant GvHD completely responding (CR) to therapy (n ¼ 2, Figure 1b) showed a strong and persistent decrease of TNFRI plasma levels at day þ 7 and þ 14, which decreased even more significantly at day þ 28. On the contrary, 4/5 GvHD patients responding partially (PR) to MSC-based therapy ( Figure 1b) showed a transient decrease of TNFRI, which however never reached values typical of HD (mean level at day 7 ¼ 2.07 ng/ml, range ¼ 1.59 --2.47; mean at day 14 ¼ 1.8 ng/ml, range ¼ 1.26 --2.9; mean at day 28 ¼ 2.59 ng/ml, range ¼ 2.07 --3.45, n ¼ 4). Around 1/5 PR (unique patient number, UPN#10) did not present any decrease of TNFRI levels even if the GvHD clinical score slightly improved (data not shown). Nonresponder (NR) patients (n ¼ 3, Figure 1b) showed stable or even increasing levels of TNFRI compared with pre-MSC values. Consistent with TNFRI, IL2Ra plasma levels showed the same trend. More in detail, aGvHD patients presented levels of IL2Ra before MSC infusion (mean level ¼ 1.58 ng/ml, range ¼ 0.72 --2.82) significantly higher (P ¼ 0.001) than HD (mean level ¼ 0.39 ng/ml, range ¼ 0.28 --0.51, n ¼ 12) (Figure 1a ). Moreover, IL2Ra resulted a suitable GvHD marker also in the case of active cGvHD, as cGvHD patients showed pre-infusion plasma levels strongly increased (mean level ¼ 2.44 ng/ml, range ¼ 0.5 --6.03, P ¼ 0.02) compared with HD. After MSC therapy, IL2Ra plasma levels stably decreased at day 7, 14 and 28 in both CR patients with steroid-resistant GvHD (Figure 1b) . In all PR patients, we observed a partial decrease at day 7 and 14 after infusion of IL2Ra plasma levels, however, holding steady above HD values (mean level at day 7 ¼ 1.06 ng/ml, range ¼ 0.45 --1.94, mean level at day 14 ¼ 0.93 ng/ml, range ¼ 0.52 --1.66). IL2Ra levels rose again at day 28 in case of GvHD reactivation (mean level at day 28 ¼ 1266, range ¼ 589 --3315). In accordance with TNFRI monitoring, NR patients showed stable or increasing IL2Ra plasma levels after MSC infusion compared with pre-therapy (Figure 1b) . To further evaluate GvHD course after MSC infusion in patients affected by GvHD with skin involvement, elafin plasma levels were monitored. Elafin is an epidermal proteinase inhibitor, induced by TNF-a, which significantly increases in the plasma of patients with severe skin GvHD, as previously reported. 5 Pre-MSC levels of elafin resulted increased in patients with moderate-to-severe skin GvHD (4stage2; UPN # 1, 2, 4, 6, 8 and 9) (mean level ¼ 56.23 ng/ml, range ¼ 13.31 --199.21), compared with HD (mean level ¼ 10.30 ng/ml, range ¼ 6.79 --12.7, n ¼ 8) (Figure 1a ). In accordance with GvHD clinical course, elafin plasma levels in UPN # 1 and 2, who responded completely to MSC infusion (Figure 1b) , decreased at day 7, 14 and 28 after therapy, below HD mean values (mean FD ¼ 2.7). PR patients (UPN # 4 and 6) showed decreasing elafin levels at day 7 and 14 after MSC (level range at day 7 ¼ 9.37 --10.23, level range at day 14 ¼ 5.39 --11.70), which rose up at day 28, upon reactivation of skin GvHD in UPN # 4. On the contrary, in UPN # 6, who experienced, at day 28 after therapy, a recurrence of GvHD with involvement of the sole gastrointestinal tract, elafin levels remained persistently under the mean levels of HD. In NR patients (UPN # 8 and 9), elafin levels stayed stably above mean HD values (mean elafin values after MSC ¼ 147.22 ng/ml, range ¼ 38.25 --200). Overall, TNFRI, IL2Ra and elafin proved to be reliable and easily measurable GvHD markers, strongly correlating with disease activity after MSC infusions. Moreover, these molecules seem to be very specific, as they are not apparently influenced by the occurrence of concomitant viral infections such as in the case of UPN # 5 and 6 (data not shown). The monitoring of these markers after MSC infusion could represent a crucial tool to identify patients that are not responding to therapy or those that, following a temporary GvHD remission, experience disease reactivation. Interestingly, we noted that NR patients showed pre-MSC levels of TNFRI, IL2Ra and elafin higher than responding patients, thus confirming the prognostic value of these markers. 4, 5 It is interesting to note that patients with similar GvHD clinical score present different pre-MSC levels of all the three biomarkers, and that these levels could be more reliable sensors of the ongoing inflammatory process and predictive of patients response to GvHD therapy. In order to clarify this point, our future purpose is to increase the number of treated patients, thus possibly establishing a correlation between biomarker plasma levels and GvHD severity/degree in patients with the same GvHD clinical score.
Moreover, in order to investigate the effect of MSC infusions on lymphocytes circulating in the peripheral blood (PB), we analyzed the ratio between the pro-inflammatory, GvHD-promoting TH1 and TH17 subsets 6, 7 and the anti-inflammatory Treg population. 8, 9 In CR patients, we observed a change in CD4 þ T-cell subsets after therapy: Tregs increased whereas Th1 and Th17 populations decreased. These variations resulted in a modification of TH1/Treg and TH17/Treg ratios, in particular, Th1/Treg ratio decreased up to 4.2 times and Th17/Treg ratio decreased up to 6 times (see Supplementary Information) . This observation is in accordance with recent reports from in vitro studies describing the ability of MSCs to induce Tregs in vitro 10, 11 and in vivo after infusion in patients with severe and treatment-refractory systemic lupus erythematosus.
12 In PR patients, we noticed a transient increase of Treg cells after MSC infusion, which, unlike CR patients, was associated with stable or increasing proportions of TH1 and TH17 in the PB. Interestingly, NR patients showed TH1/Treg and TH17/ Treg ratios significantly higher than those of CR and PR patients before and after MSC infusion. However, the levels of CD4 þ T cells are strongly influenced by other causes of inflammation such as post-transplant opportunistic infections. This was clearly shown by monitoring of UPN # 6, a PR, who experienced a viral infection few days after MSC infusion. In this patient, concomitantly with clinical improvement of GvHD a strong decrease of GvHD plasma markers was observed. However, at day 7 after therapy, unless GvHD improved, TH1/Treg and TH17/Treg ratios strongly increased, probably owing to the ongoing infection. The fact that CD4 þ T cells subsets could be severely influenced by other inflammatory events, frequently observed in the early posttransplant period, and the high inter-patients variability of their percentages in the PB, suggests caution in using these parameters to monitor patients' response to MSC therapy.
Overall, MSCs represent an effective therapeutic tool for the treatment of steroid-resistant GvHD. To support this clinical observation, we demonstrated that MSCs, upon infusion, are able to convert an inflammatory environment to a more physiological one, both at the cellular level, promoting the increase of Treg circulating in the PB, and at the molecular level, diminishing the concentration of inflammatory molecules. In attempt to clarify the mechanisms underlying this process, we analyzed the plasma levels of several immunosuppressive MSC-secreted mediators such as TSG6, IL-10, PGE2, vascular endothelial growth factor and transforming growth factor (TGF)b1, 13,14 without nonetheless observing any significant variation that could be correlated with patients' response to MSC therapy (data not shown). This observation does not exclude a possible role of these molecules in tuning inflammation in GvHD-involved tissues.
Only a very close clinical and immunological monitoring of GvHD patients infused with MSCs will clarify the immunomodulatory properties and the in vivo activity of MSC in regulating alloreactions for treating GvHD. These observations in larger cohorts of patients will provide the rational to design better clinical protocols aiming at maximizing MSC-based therapies. Moreover, we suggest TNFRI, IL2Ra and elafin as biomarkers for monitoring patients' response to MSC infusions giving precious indications to design patient-tailored anti-GVHD therapy. This issue represents an urgent clinical need as, at the moment, there is no consensus about the stratification of patients not responding to first-line treatments. The clinical management of chronic lymphocytic leukemia (CLL) patients with fludarabine-resistant disease or tumor cells with 17p deletions remains problematic. 1 High-dose glucocorticoids (HDGCs) are among the most effective treatment approaches for such patients, as well as elderly patients who cannot tolerate conventional chemotherapy. However, HDGCs are not without significant side effects and are only palliative in nature. 2 Identification of nontoxic agents that could improve the therapeutic efficacy of HDGCs would help significantly in managing these patients.
We report a case that suggests the weak androgen Danazol 3 may be such an agent. A 61-year-old female with slowly progressive Rai Stage II CLL, diagnosed 6 years earlier and characterized by the 11q deletion with high CD38 expression (44%), was being considered for first-line chemotherapy on the basis of increased fatigue and lymphocyte doubling time (Figure 1a ). The patient also had episodal angioedema from an acquired C1 esterase inhibitor deficiency related to CLL. 4 Prior to a dental procedure, her allergist prescribed Danazol 300 mg p.o. b.i.d. for 1 week to raise C1-inhibitor levels in order to prevent possible airway obstruction from oral angioedema. 5 Coincidentally, she was seen in the CLL clinic a week later where her white blood cell (WBC) count had dropped from 76 to 42 Â 10 6 cells/ml ( Figure 1a ) and she reported improvements in subjective symptoms. Another dental procedure was scheduled for the following month and the patient consented to give blood before and after the Danazol-specific death after 48 h for six female and five male patient samples. The P-value for the difference between sample means was calculated using a two-sample t-test.
